VivaZome Therapeutics presents three posters highlighting exosome purification, customisation and manufacturing at the annual ANZSEV national exosome conference
Posted: 13 November 2023 VivaZome Therapeutics Pty Ltd (“VivaZome”) is presenting three posters at the 6th annual meeting of the Australian and New Zealand Society of Extracellular Vesicles (ANZSEV) being held this week in the Barossa Valley, South…
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
Posted: 9 November 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has successfully completed enrolment in its ATH434-201 Phase 2…
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
Posted: 6 November 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the open-label safety lead-in of its integrated AIPAC-003 Phase…
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
Posted: 6 November 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new biomarker data from the TACTI-002/KEYNOTE-798 Phase II trial…
Amplia Reports Promising Clinical Data From Phase 1B Portion of the Accent Trial in Pancreatic Cancer
Posted: 6 November 2023 Amplia Therapeutics Limited is pleased to announce the completion of the Phase 1b stage of the ongoing ACCENT clinical trial in first-line patients with advanced pancreatic cancer. A safe and well tolerated dose of…
OPTISCAN ANNOUNCES CHIEF OPERATING OFFICER APPOINTMENT
Posted: 3 November 2023 Optiscan Imaging Limited (ASX: OIL) is pleased to announce a key leadership appointment reflecting the continued commercial expansion of the Company. The Company is delighted to announce the appointment of Brendan Fafiani to the…
Atmo Biosciences partners with ps.healthcare to expand Machine Learning (ML) and Artificial Intelligence (AI) capabilities
Posted: 3 November 2023 Atmo Biosciences today announced it is partnering with ps.healthcare to shape its data strategy, and create a roadmap of future applications using machine learning (ML) and artificial intelligence (AI). Atmo Biosciences is building the…
Cumming Global Centre for Pandemic Therapeutics Foundation Grants open globally
Posted: 26 October 2023 Grant applications are being sought by the Cumming Global Centre for Pandemic Therapeutics (Cumming Global Centre) for Round Two of its Foundation Grants program, which is offering a pool of up to AU$5 million in…
AD-214 PHASE I EXTENSION: FAVOURABLE TOLERABILITY AFTER THIRD DOSE
Posted: 26 October 2023 AdAlta Limited (ASX:1AD), the clinical stage company developing novel protein and cell therapeutic products from its i-body® platform, is pleased to report that all healthy volunteers in its AD-214 Phase I extension study have…
Victorian Medical Research Acceleration Fund
Posted: 26 October 2023 Closes: 1 December 2023 The Victorian Medical Research Acceleration Fund (the VMRAF) was first launched by the Victorian Government in 2017. The VMRAF is designed to capitalise on Victoria’s competitive advantages in research, increase…
Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancers
Posted: 23 October 2023 Starpharma (ASX: SPL, OTCQX: SPHRY) today announces the final positive results from its completed Phase 2 open-label clinical trial of DEP® cabazitaxel. The trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy of DEP® cabazitaxel…
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
Posted: 23 October 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces excellent new clinical data from the TACTI-002 / KEYNOTE-798…
